Publicaciones en colaboración con investigadores/as de King's College London (20)

2023

  1. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  2. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2022

  1. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis

    Molecular Autism, Vol. 13, Núm. 1

  2. Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis: Prefrontal abnormalities, executive dysfunction and symptoms severity

    Revista de Psiquiatria y Salud Mental, Vol. 15, Núm. 2, pp. 74-87

2021

  1. Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion

    Molecular Psychiatry, Vol. 26, Núm. 8, pp. 4496-4510

  2. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

  3. The role of depression in the prediction of a “late” remission in first-episode psychosis: An analysis of the OPTiMiSE study

    Schizophrenia Research, Vol. 231, pp. 100-107

2020

  1. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): Systematic review and meta-regression analysis

    Molecular Autism, Vol. 11, Núm. 1

  2. The Positive and Negative Syndrome Scale for Schizophrenia Autism Severity Scale (PAUSS) in young people with autism and schizophrenia

    Revista de Psiquiatria y Salud Mental, Vol. 13, Núm. 3, pp. 118-130

  3. Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome

    Nature Medicine, Vol. 26, Núm. 12, pp. 1912-1918

2019

  1. Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis

    Pediatrics, Vol. 144, Núm. 5

  2. Neuroanatomical deficits shared by youth with autism spectrum disorders and psychotic disorders

    Human Brain Mapping, Vol. 40, Núm. 5, pp. 1643-1653

  3. Predictors of placebo response in pharmacological clinical trials of negative symptoms in schizophrenia: A meta-regression analysis

    Schizophrenia Bulletin, Vol. 45, Núm. 1, pp. 57-68

2018

  1. Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects

    American Journal of Medical Genetics, Part A, Vol. 176, Núm. 10, pp. 2172-2181

2017

  1. Atypical age-dependency of executive function and white matter microstructure in children and adolescents with autism spectrum disorders

    European Child and Adolescent Psychiatry, Vol. 26, Núm. 11, pp. 1361-1376

2016

  1. Progressive brain changes in children and adolescents with early-onset psychosis: A meta-analysis of longitudinal MRI studies

    Schizophrenia Research, Vol. 173, Núm. 3, pp. 132-139

2015

  1. Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis

    European Child and Adolescent Psychiatry, Vol. 24, Núm. 12, pp. 1447-1459

  2. Predictors of outcome in early-onset psychosis: A systematic review

    npj Schizophrenia, Vol. 1, Núm. 1

2014

  1. A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis

    Schizophrenia Research, Vol. 158, Núm. 1-3, pp. 126-133

  2. Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra

    Revista de Psiquiatria y Salud Mental, Vol. 7, Núm. 4, pp. 166-178